Verve Therapeutics, Inc. logo

Verve Therapeutics, Inc.

NASDAQ:VERV

Overview | Financials
Company Name Verve Therapeutics, Inc.
Symbol VERV
Currency USD
Price 6.73
Market Cap 565,087,815
Dividend Yield 0%
52-week-range 4.585 - 21.04
Industry Biotechnology
Sector Healthcare
CEO Dr. Sekar Kathiresan M.D.
Website https://www.vervetx.com

An error occurred while fetching data.

About Verve Therapeutics, Inc.

Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program

Related Stocks

Merus N.V. logo

Merus N.V.

MRUS

57.26 USD

Avidity Biosciences, Inc. logo

Avidity Biosciences, Inc.

RNA

44.8 USD

Nektar Therapeutics logo

Nektar Therapeutics

NKTR

1.42 USD

Codexis, Inc. logo

Codexis, Inc.

CDXS

3.2 USD

HealthStream, Inc. logo

HealthStream, Inc.

HSTM

28.66 USD

Aurora Cannabis Inc. logo

Aurora Cannabis Inc.

ACB

6.01 USD

Evolus, Inc. logo

Evolus, Inc.

EOLS

11.77 USD

Rocket Pharmaceuticals, Inc. logo

Rocket Pharmaceuticals, Inc.

RCKT

22.5 USD

The Oncology Institute, Inc. logo

The Oncology Institute, Inc.

TOI

0.47 USD

Financials

Numbers are in millions USD

Numbers are in millions USD